3702 related articles for article (PubMed ID: 6982444)
21. [Intraocular inflammation and homeostasis of the eye].
Mochizuki M
Nippon Ganka Gakkai Zasshi; 2009 Mar; 113(3):344-77; discussion 378. PubMed ID: 19348183
[TBL] [Abstract][Full Text] [Related]
22. [Immunological studies on lymphocytes in the cerebrospinal fluid of patients with Vogt-Koyanagi-Harada disease and sympathetic ophthalmia].
Ariga H; Ohno S; Higuchi M; Matsuda H
Nippon Ganka Gakkai Zasshi; 1988 Feb; 92(2):225-8. PubMed ID: 3389270
[No Abstract] [Full Text] [Related]
23. [Increased expression of Fas and FasL mRNA in peripheral blood lymphocytes in Vogt-Koyanagi-Harada syndrome].
Chen L; Yang PZ; Zhou HY; Huang XK; Zhong H; Xie CF
Zhonghua Yan Ke Za Zhi; 2004 Aug; 40(8):507-9. PubMed ID: 15454035
[TBL] [Abstract][Full Text] [Related]
24. [Investigation of interferon system in Vogt-Koyanagi-Harada disease].
Ohno S; Kotake S; Fjuii N; Minagawa T
Nippon Ganka Gakkai Zasshi; 1982; 86(10):1574-80. PubMed ID: 6187194
[No Abstract] [Full Text] [Related]
25. p38{alpha} MAP kinase controls IL-17 synthesis in vogt-koyanagi-harada syndrome and experimental autoimmune uveitis.
Commodaro AG; Bombardieri CR; Peron JP; Saito KC; Guedes PM; Hamassaki DE; Belfort RN; Rizzo LV; Belfort R; de Camargo MM
Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3567-74. PubMed ID: 20164464
[TBL] [Abstract][Full Text] [Related]
26. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens.
Sugita S; Takase H; Taguchi C; Imai Y; Kamoi K; Kawaguchi T; Sugamoto Y; Futagami Y; Itoh K; Mochizuki M
Invest Ophthalmol Vis Sci; 2006 Jun; 47(6):2547-54. PubMed ID: 16723469
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of proinflammatory cytokine by IL-25 in Vogt-Koyanagi-Harada syndrome.
Xu M; Wang C; Tian Y; Kijlstra A; Yang P
Ocul Immunol Inflamm; 2014 Aug; 22(4):294-9. PubMed ID: 24329541
[TBL] [Abstract][Full Text] [Related]
28. [Cellular immunity in patients with Vogt-Koyanagi-Harada syndrome].
Xie CF; Huang XK; Wen SD
Yan Ke Xue Bao; 1988 Jun; 4(2):118-20. PubMed ID: 3240811
[No Abstract] [Full Text] [Related]
29. Characterization of T-cell subsets, soluble interleukin-2 receptors and interleukin-6 in Vogt-Koyanagi-Harada disease.
Kogiso M; Tanouchi Y; Miki S; Mimura Y
Jpn J Ophthalmol; 1992; 36(1):37-43. PubMed ID: 1635294
[TBL] [Abstract][Full Text] [Related]
30. IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease.
Chi W; Yang P; Li B; Wu C; Jin H; Zhu X; Chen L; Zhou H; Huang X; Kijlstra A
J Allergy Clin Immunol; 2007 May; 119(5):1218-24. PubMed ID: 17335887
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxicity tests against cultured human lung cancer cells with autologous lymphocytes activated in vitro by mitomycin C-treated tumor monolayers in the presence of T-cell growth factor.
Kimura H; Yamaguchi Y; Kadoyama C; Sato N; Fujisawa T
Jpn J Clin Oncol; 1983 Mar; 13(1):3-13. PubMed ID: 6300483
[TBL] [Abstract][Full Text] [Related]
32. Frequent immune response to a melanocyte specific protein KU-MEL-1 in patients with Vogt-Koyanagi-Harada disease.
Otani S; Sakurai T; Yamamoto K; Fujita T; Matsuzaki Y; Goto Y; Ando Y; Suzuki S; Usui M; Takeuchi M; Kawakami Y
Br J Ophthalmol; 2006 Jun; 90(6):773-7. PubMed ID: 16481377
[TBL] [Abstract][Full Text] [Related]
33. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity.
de Vries JE; Spits H
J Immunol; 1984 Jan; 132(1):510-9. PubMed ID: 6197458
[TBL] [Abstract][Full Text] [Related]
34. [Peripheral lymphocyte subsets in patients with Vogt-Koyanagi-Harada syndrome (VKH)].
Liu T; Sun SM
Zhonghua Yan Ke Za Zhi; 1993 May; 29(3):138-40. PubMed ID: 8223036
[TBL] [Abstract][Full Text] [Related]
35. Induction of regulatory T cells by infliximab in Behcet's disease.
Sugita S; Yamada Y; Kaneko S; Horie S; Mochizuki M
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):476-84. PubMed ID: 20861484
[TBL] [Abstract][Full Text] [Related]
36. Vogt-koyanagi-harada syndrome.
Fang W; Yang P
Curr Eye Res; 2008 Jul; 33(7):517-23. PubMed ID: 18600484
[TBL] [Abstract][Full Text] [Related]
37. Leptin increases in Vogt-Koyanagi-Harada (VKH) disease and promotes cell proliferation and inflammatory cytokine secretion.
Liu L; Yang P; He H; Lin X; Jiang L; Chi W; Zhao C; Zhou H
Br J Ophthalmol; 2008 Apr; 92(4):557-61. PubMed ID: 18245271
[TBL] [Abstract][Full Text] [Related]
38. [High inducibility of Epstein-Barr virus replication in B lymphocytes in Vogt-Koyanagi-Harada disease].
Minoda H; Sakai J; Sugiura M; Imai S; Osato T; Usui M
Nippon Ganka Gakkai Zasshi; 1999 Apr; 103(4):289-96. PubMed ID: 10339973
[TBL] [Abstract][Full Text] [Related]
39. IL-10 and TGF-beta immunoregulatory cytokines rather than natural regulatory T cells are associated with the resolution phase of Vogt-Koyanagi-Harada (VKH) syndrome.
Commodaro AG; Peron JP; Genre J; Arslanian C; Sanches L; Muccioli C; Rizzo LV; Belfort R
Scand J Immunol; 2010 Jul; 72(1):31-7. PubMed ID: 20591073
[TBL] [Abstract][Full Text] [Related]
40. [Vitiligo revealing Vogt -Koyanagi-Harada disease].
Amraoui ME; Zemmez Y; Bouhamidi A; Frikh R; Hjira N; Boui M
Pan Afr Med J; 2017; 27():220. PubMed ID: 28979622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
